LAG3 and neoplasm: Studies indicate that combining γδT cells with chemotherapy, immune checkpoint inhibitors (such as anti-LAG3, PD1, or PDL1 antibodies), radiotherapy, or interventional therapy can effectively mitigate TME-induced immunosuppression, thereby enhancing anti-tumor activity.